Where is Actylis located?

Actylis is headquartered in Nassau, United States.

How many employees does Actylis have?

As of Apr 30, 2026, the latest employee count at Actylis is 444.

Is Actylis a funded company?

Actylis is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Actylis rank among its competitors?

Actylis ranks 83rd amongst 1049 active competitors, of which 66 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Caidya, which secured $165M in Jan, 2025.

Who are the top competitors of Actylis?

Actylis' top competitors include WuXi AppTec, Precision Medicine Group and ANI Pharmaceuticals. Among them, Caidya secured the most recent funding round in January, 2025.

Actylis - 2026 Company Profile & Competitors

Actylis is an unfunded company based in Nassau (United States). It operates as a Provider of drug development, packaging, and analytical services for pharmaceutical industry. Actylis has not raised any funding yet. The company has 1049 active competitors, including 66 funded and 126 that have exited. Its top competitors include companies like WuXi AppTec, Precision Medicine Group and ANI Pharmaceuticals.

Company Details

Website: actylis.com
Social

Key Metrics

Location

Nassau, United States

Stage

Unfunded

Ranked

83^rd among 1049 active competitors

Employee Count

444 as on Apr 30, 2026

Similar Companies

WuXi AppTec & 1093 more

View Actylis' full profile

Actylis has not raised any funding rounds yet.

Actylis' employee count trend

Actylis has 444 employees as of Apr 26. Here is Actylis's employee count trend over the years:

Uncover Actylis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Actylis include WuXi AppTec, Precision Medicine Group and ANI Pharmaceuticals. Here is the list of Top 10 competitors of Actylis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
2nd	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Oak Investment Partners & 7 others	60/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	US Bank, Ampersand Capital & 4 others	64/100
4th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
5th	Avania 1988, Brunswick (Australia), Acquired	Provider of regulatory, clinical trials and analytic services	-	Kester Capital, Omnes Capital & 1 others	62/100
6th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
7th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	57/100
8th	Isolere Bio 2017, Durham (United States), Acquired	Developer of bioprocessing reagents for purification and manufacturing of therapeutics	$7M	Northpond Ventures, NCBiotech & 2 others	57/100
9th	Caidya 2003, Morrisville (United States), Series C	CRO focused on clinical development for phases II & III clinical trials and regulatory affair services	$373M	Qiming Venture Partners, Fidelity Investments ... & 22 others	53/100
10th	China Medical System 1992, Shenzhen (China), Public	Manufacturer of generic formulations	-	CMS Ventures	52/100
83rd	Actylis Nassau (United States), Unfunded	Provider of drug development, packaging, and analytical services for pharmaceutical industry	-	-	39/100